

Sequestrins – New small protein drugs targeting neurodegenerative disorders

<https://neurodegenerationresearch.eu/survey/sequestrins-new-small-protein-drugs-targeting-neurodegenerative-disorders/>

Principal Investigators

Stefan Ståhl

Institution

KTH Royal Institute of Technology

Contact information of lead PI Country

Sweden

Title of project or programme

Sequestrins - New small protein drugs targeting neurodegenerative disorders

Source of funding information

The Swedish Brain Foundation

Total sum awarded (Euro)

€ 108,814

Start date of award

01/07/2015

Total duration of award in years

2.5

Keywords

Research Abstract

This application is motivated by very positive and encouraging recent preclinical results (described below) from a novel therapeutic approach in the field of Alzheimer's disease (AD). The overall objective is to explore how small affinity proteins can be utilized as new types of protein drugs for neurodegenerative disorders. Affinity proteins have indeed proven suitable for targeting applications, e.g. to detect cancer tumors, but also as capturing agents for blocking of protein:protein interactions and even to sequester proteins in the circulation. This proposal intends to explore a novel and challenging biotherapy strategy. Very small affinity proteins,

termed sequestrins, that are developed in-house, will be investigated as in vivo capturing agents aimed towards future treatment of neurodegenerative disorders, with an initial focus on AD. A sequestrin is a new type of protein scaffold, based on head-to-tail-linked affibody molecules, aimed to act as “molecular tweezers” capturing aggregation-prone peptides and proteins.

Further information available at:

Types:

Investments < €500k

Member States:

Sweden

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A